OBJECTIVE: Individuals at high risk for schizophrenia may benefit from early intervention but few validated risk predictors are available. Genetic profiling is one approach to risk stratification that has been extensively validated in research cohorts, but its utility in clinical settings remains largely unexplored. Moreover, the broad health consequences of a high genetic risk of schizophrenia are poorly understood, despite being relevant to treatment decisions.
Introduction
Psychiatric disorders are common and responsible for an enormous burden of suffering 1, 2 . Approximately 18% of individuals globally suffer from mental illness every year 3 , 44.7 million of whom live in the US 4 . Early detection and intervention for serious mental illness is associated with improved outcomes [5] [6] [7] [8] . However, few reliable predictors of risk or clinical outcomes have been identified. Given the substantial heritability of many psychiatric disorders 9 and their polygenic architecture 10 , there is increasing interest in using quantitative measures of genetic risk for risk stratification 11 . Polygenic risk scores (PRSs), in particular, are easy and inexpensive to generate and can be applied well before illness onset, making them a promising candidate for clinical integration 12 . In fact, a recent study investigating the clinical utility of PRSs for several common, non-psychiatric diseases found that PRS can identify a larger fraction of high risk individuals than are identified by clinically-validated monogenic mutations, and called explicitly for evaluations of these scores in clinical settings 13 .
To date, PRSs for neuropsychiatric disorders have primarily been evaluated in highly ascertained research samples. Typically, cases have obtained a diagnosis through lengthy clinician interviews and controls have no psychiatric history ("clean" cases and controls). In order to bring PRSs to the clinic, however, they must first demonstrate association with diagnoses in real-world clinical settings, where data are often much messier. Among psychiatric disorders, schizophrenia is perhaps the best candidate for future clinical integration of PRS profiling as it is highly heritable, has the best performing PRS among psychiatric disorders in terms of proportion of phenotypic variance explained (7%) 14 , and can be difficult to distinguish from other psychiatric conditions that involve psychosis and mood disturbance. Accordingly, we 6 selected the schizophrenia PRS for the present study as it is the most viable test case for eventual clinical validation of a psychiatric PRS.
We recently established the PsycheMERGE consortium within the NIH-funded Electronic Medical Records and Genomics (eMERGE) Network 15, 16 to leverage electronic health record (EHR) data linked to genomic data to facilitate psychiatric genetic research 17 . In this first report from PsycheMERGE, we evaluated the performance of a schizophrenia PRS generated from summary statistics published by the Psychiatric Genomics Consortium 14 using EHR data on more than 100,000 patients from four large healthcare systems (Geisinger Health System, Mount
Sinai Health System, Partners Healthcare System, and Vanderbilt University Medical Center).
We assessed the relative and absolute risk for schizophrenia among individuals at the highest level of genetic risk and considered the clinical utility of the PRS for risk stratification. We also examined pleiotropic effects of the schizophrenia PRS with real-world clinical data by conducting a phenome-wide association study (PheWAS) of 1359 disease categories. To our knowledge this is the first effort to combine PheWAS effects across multiple hospital-based biobanks.
Finally, we conducted follow-up analyses to characterize the nature of the pleiotropic effects of the schizophrenia PRS. Cross-phenotype associations of polygenic liability to schizophrenia may occur in at least two scenarios 18 . In the first ("biological pleiotropy"), the PRS contributes independently to multiple phenotypes. In the second scenario ("mediated pleiotropy"), the PRS increases liability to a second disorder that occurs as a consequence of schizophrenia itself. For example, an association between schizophrenia polygenic risk and diabetes could occur because individuals diagnosed with schizophrenia are more likely to have both elevated schizophrenia PRS and to be prescribed antipsychotic medications which may 7 result in weight gain and increased liability to diabetes. In this case, the observed relationship between schizophrenia risk and diabetes is mediated by the use of antipsychotic medication.
These scenarios may be difficult to completely disentangle. However, here we use individuallevel EHR data to determine whether associations with genetic risk for schizophrenia persist after conditioning on a clinical diagnosis of schizophrenia, related psychosis, or prescription of antipsychotic medications.
Methods

Hospital-based Biobanks
Patients that consented to participate in one of four large healthcare system-based biobanks -the MyCode Community Health Initiative at the Geisinger Health System (GHS) 19 ,
the BioMe Biobank at the Mount Sinai School of Medicine (MSSM) 20 , the Partners Healthcare System (PHS) biobank 21 , or the Vanderbilt University Medical Center (VUMC) biobank (BioVU) 22 -and had available EHR and genotype data were included in these analyses. At each site, patients were recruited from the general healthcare system population without systematic recruitment for any particular disease or diagnosis. It is well known that PRS calculated from GWAS performed primarily in one ancestry demonstrates poorer performance in other ancestries as a function of differing LD structures with causal variants and lack of diversity on genotyping platforms 23, 24 . Thus, this study was limited to patients of European-American ancestry with genetic data that met standard quality control thresholds (see Quality Control of Genetic Data).
Besides these data availability and ancestry filters, no further inclusion or exclusion criteria were applied. Our final sample included 44,436 patients from GHS, 9,569 patients from MSSM, 18,461 patients from PHS, and 33,694 patients from VUMC (106,160 total participants). All 8 patients gave informed consent for biobank research for which IRB approval was obtained at each site.
Quality Control of Genetic Data
Samples were genotyped, imputed, and cleaned at each site individually, the details of which are described in Supplementary Methods. However, quality control procedures at each site followed a similar standard pipeline. DNA from blood samples obtained from biobank participants were assayed using Illumina bead arrays (OmniExpress Exome, Global Screening, MEGA, MEGA EX , or MEG BeadChips) containing approximately 700,000 to two million markers. Samples at each site were genotyped in multiple batches; indicators for genotyping platform and batch were included as covariates in the analyses. As described in Supplementary Methods, single nucleotide polymorphisms (SNPs) were excluded using filters for call rate, minor allele frequency, and heterozygosity at a minimum. Individuals were excluded for excessive missing data or sex errors; a random individual from any pair of related individuals was also excluded (pihat > .2). Principal components or self-reported ancestry was used to identify individuals of European ancestry. SNPs that passed the initial phase of quality control were imputed and then converted to best-guess genotypes where only high-quality markers were retained. Ten principal components were generated within the European sample to use as ancestry covariates in all subsequent analyses.
Polygenic Risk Scores
In order to quantify genetic risk for schizophrenia, we calculated PRSs using summary statistics from the Psychiatric Genomics Consortium genome-wide association study ( Bayesian PRS. We used PRS-CS, a Bayesian polygenic prediction method, as an alternative approach for PRS calculation. PRS-CS places a continuous shrinkage (CS) prior on SNP effect sizes and infers posterior SNP weights using GWAS summary statistics and an external LD reference panel (1000 Genomes Project European samples; N=503). PRS-CS enables multivariate modeling of local LD patterns and is robust to diverse underlying genetic architectures, and thus can increase the accuracy of PRS over conventional approaches 26 . At each site, weights for all imputed SNPs present on the 1000 Genomes reference panel and HapMap3 panel were estimated using PRS-CS, resulting in 833,502 available SNPs at GHS, 971,463 at MSSM, 833,502 at PHS, and 604,645 at VUMC. The global shrinkage parameter in the CS prior was fixed at 1 to reflect the highly polygenic genetic architecture of schizophrenia. We generated PRSs for each individual by summing all risk-associated variants weighted by the posterior effect size inferred by PRS-CS for that allele and then converted PRSs to z-scores within each healthcare system. A Python package for PRS-CS is available on GitHub repository (https://github.com/getian107/PRScs). PRSs were calculated using PLINK 1.9 27 .
EHR-derived Phenotypes
EHRs contain thousands of diagnostic billing codes from the International Classification of Diseases, 9 th and 10 th editions (ICD-9/10) which are arranged hierarchically. For example, ICD9:295 is 'schizophrenic disorders', ICD9:295.1 is 'disorganized type schizophrenia', and ICD9:295.12 is 'disorganized type schizophrenia, chronic state'; in total, the ICD9:295 category contains 71 individual ICD-9 codes. To define case status for a variety of diseases, we extracted all ICD-9 and ICD-10 codes available for participating subjects and grouped codes into 1860 disease categories (called 'phecodes') using a hierarchical structure previously developed and validated 28, 29 . For "schizophrenia and other psychotic disorders", for example, 89 individual ICD-9 codes -all 71 ICD9:295 codes and 18 related codes (e.g., 298.9, unspecified psychosis) -and 22 ICD-10 codes were mapped to this disease category.
Cases and controls were designated for each phecode. Individuals with two or more relevant ICD-9/10 codes were considered a case, those with zero relevant codes were considered a control, and individuals with only one code were excluded 30 . To enable analyses of phenomewide diagnoses that may have varying ages of onset, we did not restrict the age range of participants. The proportion of patients (cases and controls) included in a given PRS-phecode association varied depending on the prevalence of single-code individuals, but the median was 98%-100% at each site. Phecodes for which there were fewer than 100 cases were excluded from the PheWAS.
Statistical Analyses
Penetrance of schizophrenia PRS in healthcare systems. To assess the penetrance of schizophrenia PRS, we measured absolute risk (case prevalence as a function of PRS) and relative risk (ORs for the top decile of schizophrenia PRS relative to the remaining population, as well as the bottom decile) for schizophrenia and psychotic disorders. ORs were calculated at each site for both PRS methods (LD-pruned and Bayesian), regardless of the number of available cases, and then the log(OR)s were combined through fixed-effect inverse variance-weighted meta-analysis using the metafor R package (https://cran.r-project.org/web/packages/metafor/).
Schizophrenia PRS PheWAS.
We conducted PheWASs for both PRS methods in each of the four healthcare systems using all phecodes with sufficient sample size (at least 100 cases).
Logistic regressions between schizophrenia PRSs and each phecode were run with 10 ancestry principal components, median age within the medical record calculated for each individual using all of their records in the EHR, sex, genotyping platform, and genotyping batch when available, included as covariates using the PheWAS R package 29 . We used a Bonferroni correction for establishing statistical significance based on the number of phecodes tested at each site. We then meta-analyzed PheWAS effects across healthcare systems within a given PRS method with a fixed-effect inverse variance-weighted model using the PheWAS R package. Phecodes significantly associated with schizophrenia PRS in the PheWAS meta-analysis were carried forward for a follow-up analysis in which we quantified the risk of the phecode at the extremes of the PRS distribution at each site. Effects were combined across sites through meta-analysis using the metafor R package.
Sensitivity Analyses to Assess Secondary Effects of Schizophrenia.
To explore whether pleiotropic effects of the schizophrenia PRS were mediated by the diagnosis of schizophrenia itself or by the prescription of antipsychotic medications (the most common treatment for schizophrenia), we conducted four follow-up PheWAS analyses. Given the similarity of primary PheWAS results from the two PRS methods, sensitivity analyses were conducted using the LDpruned PRS method only. For each follow-up analysis, a PheWAS analysis was conducted as above, with only one of the following alterations: an additional covariate for diagnosis of psychotic disorders (phecode 295; the broadest schizophrenia-related phecode), an additional covariate for any prescriptions of antipsychotic medication, removing psychosis cases (phecode 295), and removing patients with any antipsychotic medication prescription history.
Results
Our sample included 106,160 patients (56% female) across four large US healthcare systems that had collectively received over 35 million ICD-9/10 billing codes. The median length of the electronic health record across sites ranged from 8-15 years and patients had a median range of 52-142 unique visits ( Table 1) .
Penetrance of Schizophrenia PRS in Healthcare Systems
Polygenic risk scores were robustly associated with schizophrenia in the cross-site meta- (Table S1) ; extremely similar effects were observed using the Bayesian PRS (Table S2) , as well as in each individual healthcare system (Table S3; Table S4 ). Absolute risk for schizophrenia in the top decile was 0.8% (Figure 1 ), equating to 1.9-fold increased odds of schizophrenia compared to those below the 90th percentile (95% CI, 1.5-2.4, p = 7.81 x 10 -8 ) and 3.3-fold increased odds compared to the bottom decile (95% CI, 2.1-5.2, p = 1.16 x 10 -7 )
( Figure 2 ; Table 2 ). Similarly, for the Bayesian PRS, absolute risk for the top decile was 1.0%
( Figure 1) , with an OR of 2.3 compared to the bottom 90 th percentile (95% CI, 1.9-2.9, p = 1.98 13 x 10 -14 ) and 4.6 compared to the bottom decile (95% CI, 2.9-7.3, p = 1.37 x 10 -10 ) ( Figure S1 ; Table 2 ).
Schizophrenia PRS PheWAS
After excluding codes for which no site had at least 100 cases, we conducted PheWAS using 1359 disease categories for two PRS methods. The cross-site LD-pruned PRS PheWAS meta-analysis yielded significant associations between schizophrenia PRSs and 29 medical phenotypes including schizophrenia (Table S1 ; Figure 3 ). Very similar results were observed using the Bayesian PRS (Table S2 ) and at each site (Table S3; Table S4 ). As shown, the strongest cross-site associations were with psychiatric phenotypes for which positive genetic correlations with schizophrenia have been reported, including bipolar disorder, depression, substance use disorders, and anxiety disorders 9 . We additionally found associations with personality disorders, suicidal behavior, neurological disorders, memory loss, viral hepatitis, urinary syndromes and nonspecific somatic symptoms. Obesity and synovitis were inversely associated with schizophrenia PRSs. Effect sizes for all significant phenotypes were plotted in 
Sensitivity Analyses to Assess Secondary Effects of Schizophrenia
We explored whether some of the observed associations might be mediated through a clinical diagnosis of schizophrenia or antipsychotic medication use through a series of sensitivity analyses. Nearly all associations remained significant across all sensitivity analyses (Table S5 ; Figure S2 ), although for some phecodes, there was minor variability. Nonetheless, in every analysis, phecodes related to anxiety disorders, mood disorders, substance use disorders, obesity phenotypes, urinary syndromes, and malaise and fatigue remained significant. Associations with suicidal behavior, personality disorders, neurological disorders, memory loss, synovitis and tenosynovitis, and viral hepatitis were less robust, although they remained top phenotypes consistently (Table S5 ).
Discussion
We investigated the impact of genetic risk for schizophrenia across the medical phenome in 106,160 patients from four large healthcare systems. Several findings from our analyses are particularly noteworthy. First, externally-derived polygenic risk scores for schizophrenia robustly detected risk for diagnosis of schizophrenia in real-world healthcare settings (p's < 4.48
x 10 -16 ). The effect sizes (Table 2 ) were similar to those observed for corresponding PRSs for atrial fibrillation, type 2 diabetes, inflammatory bowel disease, many common cancers 13, 31 .
Second, we leveraged the phenome-wide data available in EHRs to conduct the first psychiatric PRS PheWAS in multiple U.S. healthcare systems, revealing a range of pleiotropic relationships.
While we reported strong associations with schizophrenia, the effect sizes were more modest than those reported in schizophrenia case-control cohorts ascertained for research purposes. For example, in the original report by the PGC from which the risk scores were derived, individuals in the top decile of schizophrenia PRS relative to the bottom decile had a 7.8-20.3 increased odds of schizophrenia 14 , whereas we observed odds ratios of 3.3 and 4.6, depending on the PRS method ( Table 2 ). There are several potential reasons for this discrepancy.
First, cases in the PGC meta-analysis met relatively stringent criteria based on clinical interviews by trained research personnel, and control ascertainment often included screening for history of psychiatric or neurological disorders. This approach, typical for research samples, maximizes power for genetic discovery by extreme sampling from the tails of the genetic liability distribution. In contrast, our analysis was expressly designed to approximate use of a PRS in a typical clinical setting by applying a simple definition for both cases (two or more schizophreniarelated codes) and controls (no schizophrenia-related codes In light of this, we speculate that incorporating genetic risk could be impactful within psychiatry, especially as enhanced performance may be possible through a variety of means. For example, we implemented two PRS methods, a standard LD-pruning approach and a newer, Bayesian one, to evaluate the robustness and consistency of our results. While the differences in results were not large, the Bayesian method produced larger effect estimates overall, including for schizophrenia (Table 2) . These findings support the use of newer risk scoring methods that can incorporate more genetic variants by directly modeling LD structure. Precision of PRSs may also increase through larger discovery sample sizes 12 and with refinement of EHR-based case definitions. Nonetheless, it remains to be seen whether combining PRS risk estimates with other clinical predictors can meaningfully contribute to individualized risk assessment in psychiatry.
Schizophrenia PRSs were also associated with broader effects on mental health including increased risk for anxiety, mood, substance use, personality, and neurological disorders, as well as memory loss and suicidal behavior. Anxiety, mood, and substance use disorders have all previously been linked to genetic risk for schizophrenia 9,34-36 and our results confirm in a clinical setting that these disorders share genetic risk. Certain personality disorders have also been linked to genetic liability for schizophrenia 37, 38 (e.g., schizotypal or schizoid) and there is some evidence that personality dimensions in adolescence predict future psychopathology, including schizophrenia 39 . Similarly, family history of schizophrenia has been associated with suicidal behavior 40 . However, results from our sensitivity analyses suggested that the relationships between schizophrenia and neurological disorders, personality disorders, suicidal behavior, and memory loss may be consequences of a schizophrenia diagnosis rather than due to shared genetic risk ( Figure S2 ).
Genetic liability for schizophrenia was associated with many non-psychiatric syndromes as well, including obesity, urinary syndromes, viral hepatitis, synovitis and tenosynovitis, and malaise and fatigue. Intriguingly, obesity and morbid obesity were significantly negatively associated with schizophrenia PRSs (Table S1 ). This is somewhat surprising given the known phenotypic correlation between schizophrenia and obesity 41 . Nonetheless, three prior reports found significant inverse genetic correlations between body mass index and schizophrenia [42] [43] [44] , while a fourth reported an inverse, but non-significant relationship 45 . This may suggest that increased rates of obesity among patients with schizophrenia may be a consequence of the disease, potentially due to antipsychotic use or poor support for proper nutrition. We also found an inverse association between genetic liability for schizophrenia and diabetes, but only in sensitivity analyses controlling for a schizophrenia diagnosis or antipsychotic medication history.
It may be that this negative genetic correlation was attenuated in the primary analysis (i.e., including patients with schizophrenia and antipsychotic medication history with no statistical control) due to diabetes-promoting effects of antipsychotic medications within the same individuals that were at high genetic risk for schizophrenia 41 . In general, pleiotropic effects may have implications for risk communication if PRS testing is deployed in clinical settings in the future.
Our results should be interpreted in light of several limitations. First, due to small numbers of patients of other ancestries, our analyses were restricted to patients of European descent, and the generalizability to individuals of non-European ancestry remains to be determined. Second, our phenotype definitions relied on very simple rules and disregarded many variables of potential importance including medical history of related disorders, setting of diagnosis (i.e., in-or outpatient; physician specialty), and treatment for the disease of interest.
This was by design in order to mimic a real-world clinical population where PRSs may be implemented for clinical decision support, however, the approach is sensitive to misclassifications that occur in a clinical setting. Future work refining case and control definitions using natural language processing algorithms may improve the predictive performance of PRSs and other risk factors for clinically-derived phenotypes 47, 48 . Third, our results varied to some degree between sites (Table S3; Table S4 ), perhaps most notably for schizophrenia, suggesting that demographic and disease distributions in any given healthcare system will influence penetrance and pleiotropy. However, we tested for between-site heterogeneity for schizophrenia, and though this test has relatively low power, it showed no evidence of significant heterogeneity (p's > .45). Relatedly, disease prevalence was often lower in the overall healthcare system relative to the participants enrolled in the biobanks (a subset of those patients) (Table S6 ). In general, case prevalence in the biobanks was more representative of population-level prevalence than was that in the healthcare systems, suggesting that the discrepancies may be due to biobank patients generally having a longer duration of EHR followup and therefore more opportunity to receive a diagnosis than patients in the overall healthcare system (Table S6) . Finally, although our analyses comprise the largest test of a schizophrenia PRS in EHR data to date, additional phenotypes may show significant association in future, larger-scale PheWAS.
In conclusion, we demonstrate that an available measure of polygenic risk for schizophrenia is robustly associated with schizophrenia across four large healthcare systems using EHR data. While the observed penetrance of schizophrenia PRS is attenuated in these settings compared to prior estimates derived from research cohorts, effect sizes are comparable to those seen for risk factors commonly used in clinical settings. We also find that polygenic risk for schizophrenia has pleiotropic effects on related psychiatric disorders as well as several nonpsychiatric symptoms and syndromes. Our results provide an initial indication of the opportunities and limitations that may arise with the future application of PRS testing in healthcare systems. Age is defined as the patient's age at their most recent hospital visit in which they received an ICD-9/10 code. A visit is both patient-and date-specific, but may include many individual ICD-9/10 codes. SD, standard deviation. Overall sample case prevalence was 0.5% for schizophrenia and 1.4% for schizophrenia and related psychotic disorders. PRS, polygenic risk score; OR, odds ratio; CI, confidence interval. Manhattan plot for phenome-wide association with LD-pruned schizophrenia polygenic risk scores meta-analyzed across four healthcare systems (1359 phenotypes; 106,160 patients).
The x axis is phenotype (grouped by broad disease category) and the y axis is significance (-log 10 P; 2-tailed) of association derived by logistic regression. The red line shows phenome-wide level significance (3.7 x 10 -5 ) using Bonferroni correction and all phenotypes passing this threshold are labeled. All significant effects were positive (i.e., higher polygenic risk scores resulted in higher incidence of the phenotype) with three exceptions: morbid obesity, obesity, and synovitis and tenosynovitis. 
